Overview
Browse spinoutsLegal name
PEPGEN LIMITED
Region
East of England
Registered address
Unknown
Insolvency history
No
Spinout
Active
LTD
Company profile
Pepgen Limited
Home | PepGen
Transforming the Treatment of Neuromuscular Diseases Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline ...
CRN
11170794
Founded
2018
Age
8
Company events
Reference milestones and recent Companies House filing stream events.
3 events
24 Sep
2024
Gazette Notice Voluntary
GazetteGAZ1(A) | Transaction MzQzNTkzNjI4MmFkaXF6a2N4 | Paper/PDF filed
Published 20 Sep 2024 12:33
16 Sep
2024
Dissolution Application Strike Off Company
DissolutionDS01 | Transaction MzQzNTYxMTQzM2FkaXF6a2N4
Published 16 Sep 2024 07:44
25 Jan
2018
Incorporated
InceptionCompany registered at Companies House
Spinout profile
3 entries
Company description
PepGen, a new Oxford University Innovation spin out company.
PepGen develops peptide platform technology for the delivery of oligonucleotides to muscles, with applications in the pharmaceutical industry.
Project impact
Co-development with a pharmaceutical company in order to develop a novel multi-exon skipping approach with high efficiency for all DMD patients.
Public funding
1 award
First funded
2019
Funded years
2019
Age at first award
1 years
Projects
2019
Collaborative R&D
Lead participant
Application of a novel peptide delivery platform to nucleic acid therapeutics in degenerative and rare diseases
1 Feb 2019 to 31 Mar 2021
Awarded
£1,600,001
Total cost £2,762,622
Nucleic acid drugs are genomic medicines with the potential to transform human healthcare. Research has indicated that such therapeutics could have applications across a broad range of disease areas, including degenerative disorders, rare disorders and cancer. The use of this technology is highly promising, yet **the main challenge impeding the clinical t...
Product types
Collaborative R&D